Beam Therapeutics organizacji EBITDA margin

Jaka jest wartość EBITDA margin organizacji Beam Therapeutics?

Wartość EBITDA margin organizacji Beam Therapeutics Inc. to -35.52%

Jaka jest definicja EBITDA margin?

EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.

ttm (trailing twelve months)

EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.

EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.

EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.

Czym się zajmuję organizacja Beam Therapeutics?

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Firmy z ebitda margin podobne do Beam Therapeutics

Wartość EBITDA margin organizacji Tellurian Inc to -35.70%
Wartość EBITDA margin organizacji Quanterix Corp to -35.66%
Wartość EBITDA margin organizacji Vicinity Motor to -35.63%
Wartość EBITDA margin organizacji KNT to -35.61%
Wartość EBITDA margin organizacji Medical Properties Trust Inc to -35.61%
Wartość EBITDA margin organizacji Texmaco Infrastructure & to -35.58%
Wartość EBITDA margin organizacji Beam Therapeutics to -35.52%
Wartość EBITDA margin organizacji Oatly AB to -35.52%
Wartość EBITDA margin organizacji Green International to -35.51%
Wartość EBITDA margin organizacji Althea to -35.46%
Wartość EBITDA margin organizacji Ambarella Inc to -35.46%
Wartość EBITDA margin organizacji The Ravalgaon Sugar Farm to -35.39%
Wartość EBITDA margin organizacji Oryzon Genomics S.A to -35.35%